New and old monoclonal antibodies for the treatment of chronic lymphocytic leukemia

Luca Laurenti, Simona Sica, Laura De Padua, Barbara Vannata, Idanna Innocenti, Michela Tarnani, Giuseppe Leone, G D'Arena, S Deaglio, Dg Efremov

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Over the last few years, several new agents have been under evaluation in preclinical studies and clinical trials, showing promise in treating chronic lymphocytic leukemia (CLL). Among these agents, monoclonal antibodies (mAbs) such as rituximab and alemtuzumab have changed the natural course of the disease. Nowadays there are several new promising monoclonal antibodies under investigation against the CD20, CD23, CD37 and CD40 molecules. Application of newer monoclonal antibodies represents an area of ongoing clinical research in CLL.
Original languageEnglish
Pages (from-to)508-518
Number of pages11
JournalMINI-REVIEWS IN MEDICINAL CHEMISTRY
Volume11
Publication statusPublished - 2011

Keywords

  • Antibodies, Monoclonal
  • Antigens, CD
  • Antigens, CD20
  • Antigens, CD40
  • Antigens, Neoplasm
  • Antineoplastic Agents
  • Glycoproteins
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Receptors, IgE
  • Tetraspanins

Fingerprint

Dive into the research topics of 'New and old monoclonal antibodies for the treatment of chronic lymphocytic leukemia'. Together they form a unique fingerprint.

Cite this